1.The Normal Values of Liver Were Measured with B-Model Ultrasound
Hou YANG ; Yunhua GA ; Jinmo LIU
Journal of Third Military Medical University 1983;0(04):-
This paper has reported the data of health volunteer's liver sections, which are measured with B-Model ultrasonic scan, so as to provide the data to be for clinical reference.15 data for each volunteer were measured and treated them with statistics, the conclusions represent as follows:1. The thick diameter (i.e. anterior-posterior diameter of liver)of liver mear-suing at right midclavicular and preaxillar line are compared with body surface area and thoraxic width(transverse diameter)and thickness, the thick diameter has relevance to them closely (r= 0.3159-0.4409, P
2.An Analysis of B-type Ultrasonograpny on portal Vessels of patients with portal Hypertension
Jinmo LIU ; Hao YANG ; Yunhua GAO
Journal of Third Military Medical University 1984;0(01):-
This article is to introduce the result of the ultrasonographic examination of the patients with portal hypertension. The portal system of 42 patients with portal hypertension was examined with B-mode ultrasound and that of 109 healthy adults was also examined as control. The diameters of the portal and splenic veins of all the cases were measured. It was found that the average diameters of the potral veins of the control and the patients were 1.11?0.17 cm and 1.65?0.28 cm respectively (t = 7.3, P
3.Effect of High Dose Insulin/Euglycemia Therapy for Acute Calcium Channel Blocker Intoxication: A Systematic Review.
Jinmo YANG ; Dong Ryul KO ; Taeyoung KONG ; Young Seon JOO ; Je Sung YOU ; Sung Phil CHUNG
Journal of The Korean Society of Clinical Toxicology 2015;13(2):103-110
PURPOSE: The purpose of this study is to evaluate the effectiveness and the adverse events of high dose insulin/euglycemia therapy in acute calcium channel blocker (CCB) poisoning. METHODS: We developed a systematic search strategy and applied it to 4 electronic reference databases. We searched medical journals as well as the bibliographies of relevant articles. All forms of literature relevant to human use of high dose insulin for acute CCB poisoning were included. The literature search was conducted by two investigators in August, 2015 with publication language restricted to English and Korean. Case reports were divided between CCB overdose alone and multi-drug overdose including CCB. The effect and adverse event of high dose insulin and clinical outcome of each case were analyzed. RESULTS: Among 55 searched studies, 20 studies were included. A prospective study, a retrospective study, a systematic review study, and 17 case reports were identified. Case reports consisted of 11 CCB alone and 12 multidrug overdose cases including CCB. Although most cases described significant clinical improvements, one of them showed no beneficial effect. Several adverse events including hypoglycemia and hypokalemia were reported. No significant sequalae from adverse events was reported. CONCLUSION: Although there were many case reports demonstrating successful use of high dose insulin for CCB poisoning, the effect cannot be estimated due to a possibility of publication bias. Therefore, high dose insulin/euglycemia therapy might be considered adjunctive therapy in cases of CCB intoxication refractory for standard therapy.
Calcium Channel Blockers
;
Calcium Channels*
;
Calcium*
;
Humans
;
Hypoglycemia
;
Hypokalemia
;
Insulin
;
Poisoning
;
Prospective Studies
;
Publication Bias
;
Publications
;
Research Personnel
;
Retrospective Studies
4.Oxaliplatin/5-FU without Leucovorin Chemotherapy in Metastatic Colorectal Cancer.
Byoung Yong SHIM ; Kang Moon LEE ; Hyeon Min CHO ; Hyun Jin KIM ; Hong Joo CHO ; Jinmo YANG ; Jun Gi KIM ; Hoon Kyo KIM
Cancer Research and Treatment 2005;37(4):212-215
PURPOSE: Fluorouracil (5-FU) and leucovorin combination therapy have shown synergistic or additive effect against advanced colorectal cancer, but the frequency of mucositis and diarrhea is increased. Most previous studies have used high dose leucovorin (300~500 mg/m2). However, some studies of oxaliplatin and 5-FU with low-dose or high-dose leucovorin in Korea have shown similar response rates. Therefore, we studied the necessity of leucovorin and evaluated the objective tumor response rates and toxicities of a regimen of oxaliplatin and 5-FU without leucovorin every 2 weeks in metastatic colorectal cancer patients. MATERIALS AND METHODS: Twenty-four patients with metastatic colorectal cancer were enrolled between January 2002 and March 2003. Patients received 85 mg/ m2 of oxaliplatin on day 1, a bolus 5-FU 400 mg/m2 on day 1 and a continuous 5-FU infusion at 600 mg/m2/ 22 hours days 1 and 2, every 2 weeks. RESULTS: Of the 24 patients treated, 17 patients received previous 5FU with leucovorin and/or other chemotherapy. Three patients could not be evaluated. Five partial responses were observed with overall response rate of 21% (n=24). Of the previous chemotherapy group (n= 17), 4 partial responses were observed with response rate of 24%. Median overall survival was 18 months (range 4~32 months) and median progression free survival was 4 months (range 2~6 months). This regimen was well tolerated and only 1 grade 3 anemia was observed. CONCLUSION: Oxaliplatin/5-FU combination therapy without leucovorin achieved a relatively high response rate even in patients resistant to the previous 5-FU chemotherapy, and toxicity was minimal.
Anemia
;
Colorectal Neoplasms*
;
Diarrhea
;
Disease-Free Survival
;
Drug Therapy*
;
Fluorouracil
;
Humans
;
Korea
;
Leucovorin*
;
Mucositis
5.Phased Reduction of Cyclosporine Combined with Mycophenolate Mofetil in Renal Transplant Recipients: Three-year Results of a Prospective Study.
Jinmo KANG ; Yang Jin PARK ; Jongwon HA ; Taeseung LEE ; Jungkee CHUNG ; Yon Su KIM ; Curie AHN ; Sang Joon KIM
Journal of the Korean Surgical Society 2008;74(4):248-254
PURPOSE: Although cyclosporine (CsA) improves short-term renal graft outcomes, many paradigms reduce or withdraw this drug because of its nephrotoxicity. However, inadequate immunosuppression with azathioprine led to little success. We conducted a prospective study to define the prolonged effect of CsA reduction in stable renal transplant recipients with mycophenolate mofetil (MMF). METHODS: Thirty-nine primary renal transplant recipients were divided into two cohorts, the AZA (N=13) and the MMF cohort (N=26). Both cohorts were allowed to reduce the CsA dose up to 50% of baseline within 3 to 4 months of conversion to AZA or MMF. Graft function, clinical parameters, and adverse events were monitored for up to 3 years. RESULTS: Ccr gradually deteriorated in the AZA cohort, but was stable in the MMF cohort. There was no episode of acute rejection or graft loss observed in either cohort. CONCLUSION: The CsA dose can be reduced in combination with MMF treatment in stable renal transplant recipients after 2 years of transplantation, resulting in beneficial effects on Ccr, lipid profiles, and blood pressure.
Azathioprine
;
Cohort Studies
;
Cyclosporine
;
Immunosuppression
;
Kidney Transplantation
;
Mycophenolic Acid
;
Prospective Studies
;
Rejection (Psychology)
;
Transplants
6.Development and Clinical Implication of Post- transplant Diabetes Mellitus.
Jinmo KANG ; Jongwon HA ; Yang Jin PARK ; Taeseung LEE ; In Mok JUNG ; Jungkee CHUNG ; Yon Su KIM ; Curie AHN ; Young Min CHO ; Kyung Soo PARK ; Sang Joon KIM
The Journal of the Korean Society for Transplantation 2007;21(2):262-268
PURPOSE: It has been known that the incidence of post-transplant diabetes mellitus (PTDM) is variable according to the immunosuppressant used. The goals of this study are to uncover the factors associated with the development of PTDM and to clarify the fate of PTDM. METHODS: The medical records of 267 patients who underwent renal transplant between 1996 and December 2002 at Seoul National University Hospital were retrospectively reviewed. Patients were divided into three groups: cyclosporine group (CsA, n=179), high tacrolimus group (HFK, mean trough level during post-transplant 2 week>15 ng/m, n=33) and low tacrolimus group (LFK, mean trough level during post- transplant 2 week< or =15 ng/mL, n=55). The incidence, risk factors of PTDM and clinical fate were analyzed. RESULTS: PTDM developed in 46 (17.2%) patients. PTDM incidence of HFK group (60.6%) was significantly higher than CsA group (10.1%) and LFK group (14.5%) (P=0.000). Tacrolimus use, age at the time of transplantation (>40year), family history of diabetes and obesity (BMI>25) were the risk factors for PTDM development. Incidences of associated clinical events, such as acute rejection, cerebrovascular accident, myocardial infarction, or infection were not different between PTDM and non-PTDM group. PTDM was resolved in 13 out of 46 patients (28.3%). Only 7 out of 33 patients (21.2%) in whom PTDM persisted lost their graft. CONCLUSION: PTDM incidence was higher in HFK group. So, LFK protocol is considered to be safe and beneficial, at least in terms of PTDM. Tacrolimus as immunosuppressant, recipient, family history of DM and obesity were the risk factors of PTDM development. PTDM was reversible in 28.3% of patients. PTDM had little impact on clinical outcomes during mid-term period.
Cyclosporine
;
Diabetes Mellitus*
;
Humans
;
Immunosuppression
;
Incidence
;
Medical Records
;
Myocardial Infarction
;
Obesity
;
Retrospective Studies
;
Risk Factors
;
Seoul
;
Stroke
;
Tacrolimus
;
Transplants
7.Sustained efficacy of alpha-interferon therapy combined with Yixuesheng Capsule in treatment of chronic hepatitis B.
Qianguo MAO ; Yayong SU ; Chuncheng WU ; Zhicheng DUAN ; Jinmo TANG ; Chongi GU ; Huiqing LIANG ; Jiaen YANG ; Lijian HUANG ; Ying ZHENG ; Min WANG ; Xianqiong GONG
China Journal of Chinese Materia Medica 2012;37(4):537-540
OBJECTIVETo observe the difference between the combination therapy of alpha-interferon (IFN-alpha) therapy Yixuesheng Capsule and the monotherapy of IFN-alpha in treatment of chronic hepatitis B.
METHODA total of 288 patients with HBeAg-positive chronic hepatitis B proven by liver biopsy were included in this study. During the individualized therapy, they received hypodermic injection of IFN-alpha 1b, with 5 MU x time(-1) and three times x w(-1). Of them, 125 patients received combination therapy with Yixuesheng Capsule for three months, with 1.0 g/time and three times/d; and 163 patients received only IFN-alpha 1b (the IFN-alpha monotherapy group). After the course of therapy, all patients were followed up for at least 24 months. The intention-to-treat analysis was adopted for statistic analysis.
RESULTThe two groups showed no statistical significance by gender, age, liver necroinflammation grading, liver fibrosis staging, serum ALT levels, serum HBV DNA levels and IFN-alpha therapy course. The whole course and the 24-month follow-up visit cover all of 112 patients in the combination treatment group and 141 cases in the IFN-alpha monotherapy group. The response rates of the combination treatment group and the IFN-alpha monotherapy group were 48.0% (60/125) and 35.0% (57/163) (x = 4.980, P = 0.026) at the end of treatment, respectively, 45.6% (57/125) and 33.1% (54/163) (x2 = 4.645, P =0.031) at the end of 12-month-follow-up period, respectively, and 38.4% (48/125) and 32.5% (53/163) (x2 = 1.076, P = 0.300) at the end of 24-month follow-up period, respectively.
CONCLUSIONThe combination treatment with IFN-alpha and Yixuesheng Capsule shows a slightly better sustained efficacy on HBeAg-positive chronic hepatitis B patients compared with IFN-alpha monotherapy.
Adult ; Capsules ; Combined Modality Therapy ; Drugs, Chinese Herbal ; therapeutic use ; Female ; Follow-Up Studies ; Hepatitis B, Chronic ; drug therapy ; Humans ; Interferon-alpha ; therapeutic use ; Male ; Treatment Outcome
8.Randomized, Multicenter, Phase III Trial of Heptaplatin 1-hour Infusion and 5-Fluorouracil Combination Chemotherapy Comparing with Cisplatin and 5-Fluorouracil Combination Chemotherapy in Patients with Advanced Gastric Cancer.
Kyung Hee LEE ; Myung Soo HYUN ; Hoon Kyo KIM ; Hyung Min JIN ; Jinmo YANG ; Hong Suk SONG ; Young Rok DO ; Hun Mo RYOO ; Joo Seop CHUNG ; Dae Young ZANG ; Ho Yeong LIM ; Jong Youl JIN ; Chang Yeol YIM ; Hee Sook PARK ; Jun Suk KIM ; Chang Hak SOHN ; Soon Nam LEE
Cancer Research and Treatment 2009;41(1):12-18
PURPOSE: Heptaplatin (Sunpla) is a cisplatin derivative. A phase IIb trial using heptaplatin resulted in a 34% response rate with mild nephrotoxicity. We conducted a randomized phase III trial of heptaplatin plus 5-FU compared with cisplatin plus 5-FU in patients with advanced gastric cancer. MATERIALS AND METHODS: One hundred seventy-four patients (heptaplatin, n=88; cisplatin, n=86) from 13 centers were enrolled. The eligibility criteria were as follows: patients with pathologically-proven adenocarcinoma, chemonaive patients, or patients who had received only single adjuvant chemotherapy, and who had a measurable or evaluable lesion. On day 1, heptaplatin (400 mg/m2) or cisplatin (60 mg/m2) was given over 1 hour with 5-FU (1 gm/m2) on days 1~5 every 4 weeks. RESULTS: At the time of survival analysis, the median overall survival was 7.3 months in the 5-FU + heptaplatin (FH) arm and 7.9 months in the 5-FU + cisplatin (FP) arm (p=0.24). Of the FH patients, 34.2% (complete response [CR], 1.3%; partial response [PR], 32.9%) experienced a confirmed objective response compared with 35.9% (CR 0%, PR 35.9%) of FP patients (p=0.78). The median-time-to-progression was 2.5 months in the FH arm and 2.3 months in the FP arm. The incidence of neutropenia was higher with FP (28%) than with FH (16%; p=0.06); grade 3~4 nausea and vomiting were more frequent in the FP than in the FH arm (p=0.01 and p=0.05, respectively). The incidence of increased proteinuria and creatininemia was higher with FH than with FP; however, there was no statistical difference. There were no treatment-related deaths. CONCLUSION: Heptaplatin showed similar effects to cisplatin when combined with 5-FU in advanced gastric cancer patients with tolerable toxicities.
Adenocarcinoma
;
Arm
;
Chemotherapy, Adjuvant
;
Cisplatin
;
Drug Therapy, Combination
;
Fluorouracil
;
Humans
;
Incidence
;
Malonates
;
Nausea
;
Neutropenia
;
Organoplatinum Compounds
;
Proteinuria
;
Stomach Neoplasms
;
Vomiting